Orion Oyj

Equities

ORNBV

FI0009014377

Pharmaceuticals

Real-time Estimate Tradegate 12:19:06 2024-03-28 pm EDT 5-day change 1st Jan Change
34.54 EUR +0.16% Intraday chart for Orion Oyj 0.00% -12.22%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Orion to Continue Reviewing Outsources Options for Finnish Plant as Change Negotiations Complete MT
Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024 CI
Orion Corporation Announces Board and Committee Appointment CI
Orion Corporation Approves Board Appointments CI
Orion Corporation Approves Dividend for the Financial Year Ended 31 December 2023, Payable on 3 April 2024 and 23 October 2024 CI
Orion Unveils Partnership with Save the Children Finland MT
Orion Explores Potential Outsourcing of Kuopio Plant’s Production Operations MT
Transcript : Orion Oyj, 2023 Earnings Call, Feb 13, 2024
Orion Provides FY24 Sales, Operating Profit Guidance MT
Orion Oyj Announces Retirement of Mikael Silvennoinen as Board Member CI
Orion Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Orion Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Orion Oyj Proposes Dividend for the Financial Year Ended on 31 December 2023, Payable on 3 April 2024 and 23 October 2024 CI
Orion Oyj Provides Earnings Guidance for the Year 2024 CI
Orion Inks License Deal With Newel Health for Digital Therapeutic MT
Orion Corporation and Newel Health Enter into Licensing Agreement for Digital Therapeutic(DTx) ODD-403 (?Rohkea?) in pain CI
Orion CFO to Step Down, Successor Appointed MT
Orion Oyj Announces CFO Changes CI
Orion Flags EUR31 Million Gain in FY23 from Pension Fund’s Insurance Portfolio Transfer MT
Orion, Glykos Finland Tie Up for Development of Antibody-drug Conjugates MT
Orion Corporation and Glykos Finland Oy Announce Research Collaboration and Licensing Agreement to Develop Next-Generation Adcs CI
Orion Starts Two Late-stage Studies for Investigational Prostate Cancer Therapy MT
Navamedic Enters Agreement with Orion for Distribution of Parkinson's Drug Across Europe MT
Navamedic ASA and Orion Corporation Sign Non-Binding Term Sheet for Flexilev® in Europe CI
Orion Corporation Announces Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database CI
Chart Orion Oyj
More charts
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - generic, OTC and biosimilar drugs (43.4%); - patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - animal health products (8.7%); - pharmaceutical ingredients and outsourcing services (6.2%). Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%). Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
34.48 EUR
Average target price
39.9 EUR
Spread / Average Target
+15.72%
Consensus
  1. Stock
  2. Equities
  3. Stock Orion Oyj - Nasdaq Helsinki
  4. News Orion Oyj
  5. Orion Oyj : Teams Up With Finnish Red Cross Blood Service to Develop Cell Therapies for Cancer